Adopt 17 Cal. Code of Regs. section 100300 to read:

§ 100300. Intellectual Property Requirements for Non-Profit Organizations - Scope.

The regulations of this chapter apply to all CIRM grant awards issued on or after the effective date of these regulations. By accepting a CIRM grant award, the grantee agrees to comply with the provisions of these regulations. Any new or amended regulations adopted by the Independent Citizen's Oversight Committee ("ICOC") will be applied to currently active grants on the start date of the next non-competitive renewal period after the effective date of the regulations. A currently active grant is a grant that is still in the Project Period or a grant for which CIRM funds are still being expended. New or amended regulations adopted after the expiration of the Project Period of a grant and after all CIRM funds for the grant have been expended will apply on January 1 following the effective date of the new or amended regulation, unless specified otherwise in the regulation. Principal investigators, program directors and organizational officials with active CIRM grants will receive notification of revised grant terms and conditions or revised editions of the CIRM Grants Administration Policy as they are released. In addition, all revisions to these regulations will be posted on the CIRM website at www.cirm.ca.gov. Failure by a principal investigator or other person affiliated with the grantee to have notification shall not excuse non-compliance as long as the CIRM has notified the grantee.

Note: Authority cited: California Constitution, article XXXV; Section 125290.40, subd.(j), Health and Safety Code.

Reference: Section 125290.30, Health and Safety Code.

Adopt 17 Cal. Code of Regs. section 100301 to read:

§ 100301. Intellectual Property Regulations - Definitions.

(a) "Authorized Organizational Official." The individual, named by the applicant organization, who is authorized to execute agreements that legally bind the applicant institution to assume the obligations imposed by the laws, regulations, requirements, and conditions that apply to grant applications or grant awards.

(b) "Award." The provision of funds by CIRM, based on an approved application and budget or progress report, to an organizational entity or an individual to carry out a project or activity.

(c) "Bayh-Dole Act." Section 6(a) of the federal Patent and Trademark Law Amendments Act as amended (35 U.S.C. §§ 200 212).

(d) "Biomedical Materials." Entities of biomedical relevance first produced as a consequence of CIRM-funded scientific research including but not limited to unique research resources such as synthetic compounds, organisms, cell lines, viruses, cell products, cloned DNA, as well as DNA sequences, mapping information, crystallographic coordinates, and spectroscopic data. Specific examples include specialized and/or genetically defined cells, including normal and diseased human cells, monoclonal antibodies, hybridoma cell lines, microbial cells and products, viruses and viral products, recombinant nucleic acid molecules, DNA probes, nucleic acid and protein sequences, certain types of animals including transgenic mice and other property such as computer programs.

(e) "Data." The recorded factual material commonly accepted in the scientific community as necessary to validate research findings, but not any of the following: preliminary

analyses, drafts of scientific papers, plans for future research, peer reviews, or communications with colleagues. This "recorded" material excludes physical objects (e.g., laboratory samples).

(f) "Exclusive License." Any License Agreement for a CIRM-funded patented invention that permits the licensee to exclusively exercise any commercial right within the state of California or the United States, or within any field of use, or for any licensed product or licensed purpose.

(gf) "Grantee/Grantee Organization." The non-profit organization awarded a grant by CIRM that is legally responsible and accountable for the use of the funds provided and for the performance of the grant-supported project or activity. The grantee is the entire legal entity even if a particular component is designated in the NGA. All University of California grantee campuses shall be considered as separate and individual Grantee Organizations.

(hg) "Grantee Organization's Share." The revenues received by a Ggrantee Oorganization under a commercial license of a CIRM-funded patented invention remaining after deducting the direct costs associated with patents and patent applications claiming inventions made under CIRM funding and the inventor's share of those revenues.

(ih) "Invention." ~~[As used in the Bayh-Dole Act, i.e.,]~~A discovery that is or may be patentable (novel, useful and non-obvious) or otherwise protectable under Title 35 of the United States Code.

(ji) "Invention Disclosure." A description of an invention that, if made public, would trigger a patent bar under U.S. Patent Law.

(kj) "Invention Disclosure Form." A written notification to CIRM that a CIRM-funded patentable invention has been made.

(lk) "Invention Utilization Report." Applicable to Ggrantee oOrganizations that have previously filed an Invention Disclosure Form, this annual report is a written description of efforts made by authorized organizational officials to commercialize CIRM-funded patentable inventions. This report will include information about the status of development, date of first commercial sale or use and any licensing fees and/or gross royalties received by the Ggrantee Oorganization relating to CIRM-funded patented inventions.

(ml) "Inventor." A person who thinks of, finds, discovers, or creates an invention during the project period of a CIRM grant and using CIRM funds as determined under U.S. Patent Law.

(nm) "License Agreement." An agreement by which a patent owner allows another party to make, use, sell, offer to sell, and/or import an invention protected by a patent.

(on) "Licensing Activities." Actions taken by authorized organizational officials, the desired outcome of which is a contractual agreement under which the Ggrantee oOrganization grants permission to another party to use intellectual property under specific conditions.

(po) "Licensing Fee." A one-time cost payable by a licensee to the patent owner typically associated with execution of a license agreement.

(qp) "Materials Transfer Agreement." A document ("MTA") which governs the exchange of a substance, element or item (material) to another party for the purposes of research. It limits the commercial exploitation of the material without the permission of the provider party.

(rq) "No-Cost License." An agreement to practice an invention protected by a patent where no licensing fee, royalty or any other payment is required of the licensee.

(sr) "Non-Profit Organization." A (1) university or other institution of higher education or another organization of the type described in 501(c)(3) of the Internal Revenue Code of 1986,

as amended (26 U.S.C. 501 (c)(3)) and is exempt from taxation under 501 (a) of the Internal Revenue Code (26 U.S.C. 501 (a)), or (2) any other non-profit scientific or educational organization qualified under a state non-profit organization statute whose organizational charter provides that (a) the organization is not organized or operated for the private ~~grain~~ gain of any person, (b) no part of the organization's net income or assets shall inure to the benefit of any person, and (c) the organization's net assets upon dissolution shall be distributed to a non-profit fund, foundation or corporation which is organized and operated exclusively for charitable purposes.

(t~~s~~). "Notice of Grant Award." The document that notifies the grantee and others that an award has been made, contains or references all terms and conditions of the award, and documents the obligation of CIRM funds.

(u~~t~~) "Patentable Invention." A novel, useful and non-obvious invention that advances science and enables new useful applications including therapeutics or diagnostic tools, as determined under relevant patent law.

(v~~u~~) "Person." A "person" means an individual, proprietorship, firm, partnership, joint venture, syndicate, business trust, company, corporation, limited liability company, ~~a~~association, or any other organization or group of persons acting in concert.

(w~~v~~) "Principal Investigator/Program Director." The principal investigator ("PI") or program director ("PD") is an individual designated by the grantee to direct the project or activity being supported by the grant. He or she is responsible and accountable to the grantee and CIRM for the proper conduct of the project or activity. For training programs or similarly structured programs, the PD is the same as the PI.

(x~~w~~) "Project period." The total amount of time for which CIRM promises to fund a grant and authorizes a grantee to conduct the approved work of the project described in the application.

Note: Authority cited: California Constitution, article XXXV; Section 125290.40, subd.(j), Health and Safety Code.

Reference: Section 125290.30, Health and Safety Code.

Adopt 17 Cal. Code of Regs. section 100304 to read:

§ 100304. Biomedical Materials.

Grantees shall share biomedical materials first created under CIRM funding and described in published scientific articles for research purposes in California within 60 days of receipt of a request and without bias as to the affiliation of the requestor unless legally precluded. Under special circumstances, exceptions to the above are possible with approval by CIRM. Alternatively, authors may provide requestors with information on how to reconstruct or obtain the material. Such ~~M~~materials are to be shared without cost or at the actual cost of providing the material without an allocation of costs for overhead, research, discovery or other non-direct costs of providing the material.

Note: Authority cited: California Constitution, article XXXV; Section 125290.40, subd.(j), Health and Safety Code.

Reference: Section 125290.30, Health and Safety Code.

Adopt 17 Cal. Code of Regs. section 100306 to read:

§ 100306. Licensing CIRM-Funded Patented Inventions.

(a) A Grantee Oorganizations shall assume responsibility for licensing activities including identification of potential licensees, negotiation of license agreements and documentation of development progress for licenses relating to CIRM-funded patented inventions. In licensing CIRM-funded patented inventions, licensees a Grantee Organizations agrees that grantee organizations it shall retain the right to practice the use of its CIRM-funded patented inventions for any non-profit its non-commercial purposes., including sponsored research and collaborations. A Grantee Organization agrees to make its CIRM-funded patented inventions readily accessible on reasonable terms, directly or through licensees, to other Grantee Organizations for non-commercial purposes, upon request from a Grantee Organization. Grantee organizations are required to submit a licensing activitiesan Invention Utilization Rreport relevant to CIRM-funded patented inventions on an annual basis.

(b) Grantee organizations shall negotiate non-exclusive licenses of CIRM-funded inventions whenever possible. Nevertheless, grantee organizations may negotiate and award exclusive licenses for CIRM-funded inventions if such licenses are necessary to provide economic incentives required to enable commercial development and availability of the inventions. In due diligence relating to such exclusive licenses, grantee organizations shall document development and commercialization capabilities of the intended licensee, and include terms in the license agreement addressing all relevant therapeutic and diagnostic uses for which the invention is applicable and the licensee agrees to diligently develop.

(c) In exclusive license agreements, grantee organizations shall include terms for commercial development plans to bring the invention to practical application. Such provisions shall include commercial development milestones and benchmarks so that development can be assessed and monitored.

(d) Grantee organizations shall grant exclusive licenses involving CIRM-funded patented inventions relevant to therapies and diagnostics only to persons that agree to have a plan in place at the time of commercialization to provide access to resultant therapies and diagnostics for uninsured California patients. In addition, such licensees will agree to provide to patients whose therapies and diagnostics will be purchased in California by public funds the therapies and diagnostics at a cost not to exceed the federal Medicaid price. The CIRM may make access plans available for review by the ICOC on an annual basis.

(e) Grantee organizations shall monitor the performance of exclusive licensees of CIRM-funded patented inventions to ensure that the licensed invention is developed in a timely fashion. Remedies for failure to develop may include modification or termination of a license by the grantee in the event that a licensee is unable to fully develop the rights granted.

(f) Grantee organizations shall negotiate relevant and specific grounds for modification or termination of the license. Examples would include failure to meet agreed-upon commercialization benchmarks, failure to keep the licensed invention reasonably accessible to the public for research purposes, and failure to reasonably meet the agreed-upon plan for access to resultant therapies as described in subdivision (d) of this regulation.

(g) Grantee organizations shall monitor the commercial development activities of the licensees to determine compliance with the terms of the license agreement and include reports of monitoring activities annually to the CIRM.

(h) Grantee organizations shall take administrative action to modify or terminate license rights where necessary and report such action to the CIRM.

Note: Authority cited: California Constitution, article XXXV; Section 125290.40, subd.(j), Health and Safety Code.

Reference: Section 125290.30, Health and Safety Code.